Suppr超能文献

慢性淋巴细胞白血病和华氏巨球蛋白血症中的治疗相关髓系肿瘤。

Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom's Macroglobulinemia.

机构信息

Division of Hematology, Niguarda Ca' Granda Hospital, Milano, Italy.

出版信息

Mediterr J Hematol Infect Dis. 2011;3(1):e2011031. doi: 10.4084/MJHID.2011.031. Epub 2011 Jul 9.

Abstract

Secondary myelodysplasia (MDS) and acute myeloid leukemia (AML) are frequent long term complications in Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM) patients. Although disease-related immune-suppression plays a crucial role in leukemogenesis there is great concern that therapy may further increase the risk of developing these devastating complications.Nucleoside analogs (NA) and alkylating agents are considered appropriate agents in the treatment of both CLL and WM patients. Prolonged immunosuppression related to NA therapy and the incorporation of these agents or their metabolites into DNA, with potentially mutagenic action, leads to speculation that their therapeutic use might be responsible for an increased incidence of second cancer especially when combined with other DNA damaging agents like alkylating agents.In this review the published studies considering the occurrence of secondary MDS and AML in CLL and WM patients are reported and the potential role of chemotherapeutic agents in leukemogenesis is discussed.

摘要

继发性骨髓增生异常综合征(MDS)和急性髓系白血病(AML)是慢性淋巴细胞白血病(CLL)和华氏巨球蛋白血症(WM)患者的常见长期并发症。虽然疾病相关的免疫抑制在白血病发生中起着至关重要的作用,但人们非常担心治疗可能会进一步增加发生这些毁灭性并发症的风险。核苷类似物(NA)和烷化剂被认为是 CLL 和 WM 患者治疗的合适药物。与 NA 治疗相关的长期免疫抑制以及这些药物或其代谢物掺入 DNA 中,具有潜在的诱变作用,这导致人们推测它们的治疗用途可能会导致第二癌症的发生率增加,尤其是当与其他 DNA 损伤剂如烷化剂联合使用时。在这篇综述中,报告了考虑 CLL 和 WM 患者继发性 MDS 和 AML 发生的已发表研究,并讨论了化疗药物在白血病发生中的潜在作用。

相似文献

1
Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom's Macroglobulinemia.
Mediterr J Hematol Infect Dis. 2011;3(1):e2011031. doi: 10.4084/MJHID.2011.031. Epub 2011 Jul 9.
4
PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53.
Cancer Biol Ther. 2015;16(5):799-806. doi: 10.1080/15384047.2015.1026482.
10
Chronic myeloid leukemia in Waldenström's macroglobulinemia.
Arch Intern Med. 1981 Sep;141(10):1349-51.

引用本文的文献

1
Relapsed Waldenstrom's Macroglobulinemia and Therapy-Related Myelodysplastic Syndrome with Complex Cytogenetics: A Treatment Dilemma.
Case Rep Oncol. 2023 May 23;16(1):351-356. doi: 10.1159/000530328. eCollection 2023 Jan-Dec.
2
Secondary malignancies and survival of FCR-treated patients with chronic lymphocytic leukemia in Central Europe.
Cancer Med. 2023 Jan;12(2):1961-1971. doi: 10.1002/cam4.5033. Epub 2022 Oct 7.
3
Waldenström macroglobulinemia treatment algorithm 2018.
Blood Cancer J. 2018 May 1;8(4):40. doi: 10.1038/s41408-018-0076-5.
5
Therapy related acute myeloid leukemia with t(10:16): a rare entity.
Hematol Rep. 2011 Oct 19;3(3):e23. doi: 10.4081/hr.2011.e23. Epub 2011 Dec 15.

本文引用的文献

4
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.
Blood. 2011 Mar 17;117(11):3016-24. doi: 10.1182/blood-2010-08-304683. Epub 2011 Jan 18.
6
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
Leukemia. 2010 Dec;24(12):2056-62. doi: 10.1038/leu.2010.218. Epub 2010 Oct 21.
9
Incidence and susceptibility to therapy-related myeloid neoplasms.
Chem Biol Interact. 2010 Mar 19;184(1-2):39-45. doi: 10.1016/j.cbi.2009.12.013. Epub 2009 Dec 21.
10
Epigenetic changes in therapy-related MDS/AML.
Chem Biol Interact. 2010 Mar 19;184(1-2):46-9. doi: 10.1016/j.cbi.2009.10.013. Epub 2009 Oct 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验